Cargando…
Cannabinoids in Glioblastoma Therapy: New Applications for Old Drugs
Glioblastoma (GBM) is the most malignant brain tumor and one of the deadliest types of solid cancer overall. Despite aggressive therapeutic approaches consisting of maximum safe surgical resection and radio-chemotherapy, more than 95% of GBM patients die within 5 years after diagnosis. Thus, there i...
Autores principales: | Dumitru, Claudia A., Sandalcioglu, I. Erol, Karsak, Meliha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964193/ https://www.ncbi.nlm.nih.gov/pubmed/29867351 http://dx.doi.org/10.3389/fnmol.2018.00159 |
Ejemplares similares
-
Dynein Light Chain Protein Tctex1: A Novel Prognostic Marker and Molecular Mediator in Glioblastoma
por: Dumitru, Claudia Alexandra, et al.
Publicado: (2021) -
Stable Adult Hippocampal Neurogenesis in Cannabinoid Receptor CB2 Deficient Mice
por: Mensching, Leonore, et al.
Publicado: (2019) -
Monitoring Cannabinoid CB2 -Receptor Mediated cAMP Dynamics by FRET-Based Live Cell Imaging
por: Mensching, Leonore, et al.
Publicado: (2020) -
Systematic Affinity Purification Coupled to Mass Spectrometry Identified p62 as Part of the Cannabinoid Receptor CB2 Interactome
por: Sharaf, Ahmed, et al.
Publicado: (2019) -
Editorial: Therapeutic potential of the cannabinoid CB2 receptor
por: Smoum, Reem, et al.
Publicado: (2022)